Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies
Case ID:
TAB-2404
Web Published:
12/6/2022
mEpoR-/- hEpoR+: The mouse Erythropoietin Receptor knockout that contains a human Erythropoietin Receptor transgene can be used to define the potency of recombinant erythropoietin preparations used to treat anemia associated with chronic kidney disease.
Erythropoietin, acting by binding to Erythropoietin receptors (EpoR) on erythroid progenitor cells, is required for erythropoiesis. Absence of erythropoietin or the EpoR in mice interrupts erythropoiesis in the fetal liver and result in death at embryonic day 13.5. An 80-kb human EpoR transgene bred onto a mouse EpoR null background (provided by F. Constantini of Columbia University) restored effective erythropoiesis in the EpoR null mouse. Erythropoietin preparations made utilizing recombinant DNA technology are used in the treatment of anemia in chronic kidney disease and other critical illnesses. The mouse EpoR null mouse containing the human EpoR transgene can be used to define the potency of erythropoietin preparation in humans.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=mEpoR_Knockout%2fTg(hE poR)_Mouse_Model_for_Anemia_and_Renal_Function_Studies
Keywords:
ACXXXX
AXXXXX
EPO
EpoR
Erythropoietin
ICXXXX
IDXXXX
IXXXXX
Mice
RECEPTOR
Bookmark this page
Download as PDF
For Information, Contact:
Betty Tong
Technology Licensing Specialist
NIH Technology Transfer
301-451-7836
tongb@niddk.nih.gov